Stockscreener 앱 받기
1.20
8.40%
-0.11
시장 영업 전:
1.24
0.04
+3.33%
전일 마감가:
$1.31
열려 있는:
$1.31
하루 거래량:
150.23K
Relative Volume:
0.81
시가총액:
$19.09M
수익:
$345.00K
순이익/손실:
$-11.25M
주가수익비율:
-1.6627
EPS:
-0.7217
순현금흐름:
$-16.70M
1주 성능:
-7.69%
1개월 성능:
-25.47%
6개월 성능:
+8.11%
1년 성능:
+18.81%
1일 변동 폭
$1.19
$1.31
1주일 범위
$1.19
$1.40
52주 변동 폭
$0.7687
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
명칭
Allarity Therapeutics Inc
전화
401-426-4664
주소
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.20 | 20.52M | 345.00K | -11.25M | -16.70M | -0.7217 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-28 | 개시 | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc 주식(ALLR)의 최신 뉴스
Enterprise value to EBITDA forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Tranche Update on Allarity Therapeutics, Inc.'s Equity Buyback Plan announced on March 3, 2025. - marketscreener.com
Allarity Wins Key U.S. Patent for Stenoparib Diagnostic - TipRanks
Allarity Therapeutics (NASDAQ: ALLR) wins key DRP patent and secures shareholder backing - Stock Titan
Enterprise value to revenue forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Allarity receives U.S. patent for stenoparib diagnostic test - Investing.com
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic - GlobeNewswire
Price to earnings forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Price to book forward of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
Allarity Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLR) - TradingView
ALLR Forecast — Price Target — Prediction for 2027 - TradingView
Is Allarity Therapeutics, Inc. (ALLR) outperforming other medical stocks this year? - MSN
Allarity Therapeutics Inc (ALLR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Allarity Therapeutics Showcases Phase 2 Stenoparib Trial Progress in Advanced Ovarian Cancer at ESMO 2026 - Minichart
Form 8K Allarity Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Allarity Therapeutics (NASDAQ: ALLR) showcases Phase 2 stenoparib ovarian cancer trial - Stock Titan
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 - Investing News Network
Allarity to present trial poster at cancer congress - Investing.com
Allarity to present trial poster at cancer congress By Investing.com - Investing.com Canada
Allarity Therapeutics to Present Trial-in-Progress Poster - GlobeNewswire
Allarity Therapeutics Inc (ALLR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Allarity Therapeutics Inc (ALLR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allarity Therapeutics Inc (ALLR) Institutional Confidence - TradingKey
Allarity Therapeutics Inc (ALLR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Allarity Therapeutics Inc (ALLR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Allarity Therapeutics Inc (ALLR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Allarity Therapeutics Inc (ALLR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Allarity Therapeutics Inc (ALLR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
ALLR Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineNet Profit Margin - newsline.com
ALLR Maintained by Ascendiant Capital -- Price Target Raised to $10.25 - GuruFocus
ALLR Q1 2026 Earnings: EPS Surprises to the Upside as Clinical Advances ContinueROA Comparison - dars.gov.et
Allarity Therapeutics (ALLR) Slides 5.3% as Stock Tests Critical Support LevelGap Fill Strategy - newsline.com
Are medical stocks lagging Allarity Therapeutics, Inc. (ALLR) this year? - MSN
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? - Yahoo Finance
Amended and Restated Management Services Agreement Between Allarity Therapeutics, Inc. and Ljungaskog Consulting AB Effective June 1, 2026 - Minichart
Allarity Therapeutics Updates CEO Management and Compensation Agreement - TipRanks
Allarity (NASDAQ: ALLR) updates CEO pay and severance terms - Stock Titan
Number of shareholders of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
ALLR Q1 2026 Earnings: Narrower Loss Surprises as Pre-Revenue Biotech Advances PipelineGuidance Downgrade Alert - The Legal Advocate
ALLRAllarity Therapeutics Inc Options - Finviz
Allarity Therapeutics (ALLR) Faces Selling Pressure, Holds Above Key SupportVolatility Smile - thelegaladvocate.com
RKTO Stock Price and Chart — NASDAQ:RKTO - TradingView
Allarity Therapeutics (ALLR) Slides 4.8% in Session; Key Support Levels in FocusGEX Level - newsline.com
Allarity Therapeutics (ALLR) Surges 6.6% as Volume Picks Up, Testing Key ResistanceOption Breadth - The Legal Advocate
Allarity (ALLR) Posts Q1 2026 Earnings Beat — Here's What Drove ItPre-Announcement Alert - The Legal Advocate
Allarity (ALLR) Delivers Q1 2026 Beat — EPS $-0.17 vs $-0.22 ExpectedEarnings Season Preview - The Legal Advocate
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
Allarity Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Allarity Therapeutics Inc (ALLR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
0.74%
자본화:
|
볼륨(24시간):